Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more ...

Epileptic seizures alter sleep by prolonging the stage that's central to memory formation, potentially predisposing the brain to "remember" how to trigger subsequent seizures more easily, a small ...

A pioneering gene therapy could help treat a rare seizure disorder called Dravet syndrome, according to new clinical trial ...

The National Institute for Health and Care Excellence (NICE), said clinicians should discuss the risk of SUDEP with people who have seizures during sleep and, if appropriate, to i ...

Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7 ...

Xenon plans to submit a new drug application for azetukalner to the U.S. Food and Drug Administration for the treatment of focal onset seizures in the third quarter of 2026. ・CEO Ian Mortimer said ...

Researchers have discovered that mutations in the FOXJ3 gene act as a "master switch" failure, disrupting how the brain ...

An insightful mini-review published in Genomic Psychiatry synthesizes the rapidly expanding landscape of molecular genetic research on common epilepsies, assembling evidence from genome-wide ...

Cassava Sciences has rebranded as Filana Therapeutics, shedding the baggage associated with the old name as the biotech plants itself in a new therapeutic area. | Cassava Sciences has rebranded as ...

A new experimental drug is showing remarkable promise for children with Dravet syndrome, a severe genetic form of epilepsy.

Findings published by The BMJ reinforce previous research linking use of the antiseizure drug valproate during pregnancy to neurodevelopmental disorders such as ADHD and autism in children, and ...